Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control: a Single Arm Controlled Trial
Who can join
Ages 8 to 13 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: 1. Provision of consent 2. Non-Chinese Ethnicity 3. Age: ≥8 and ≤13 years at enrollment 4. Myopia: Spherical equivalent refractions (SERs) under cycloplegia: -1.00 to -5.00 diopters (D) 4\) Astigmatism of 2.50 D or less 5) Anisometropia of 1.50 D or less 6) Corrected monocular logMAR visual acuity (VA): 1.0 or better 7) Consent to participate in random allocation of grouping 8) Fluent in English 9) Willing and able to participate in all required activities of the study6) Corrected monocular logMAR visual acuity (VA): 1.0 or better Exclusion Criteria: 1. Strabismus and binocular vision abnormalities in either eye 2. Ocular abnormalities in either eye or other systemic abnormalities that affect participate in all required activities of the study. 3. Other reasons, including but not limited to severe physical and cognitive disability, that the physician may consider inappropriate for enrollment 4. Noncompliance with treatment 5. Children whose parents do not sign informed consent
About the study
Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.
What is being tested
- Low-level Red Light Therapy Device (device)
Sponsor: University of California, San Francisco · Participants: 90 · Started: Jul 14, 2023
Contact the study team
- Tiffany Chen, MD · Phone: 4155143503
Official record on ClinicalTrials.gov — NCT05606237
Locations in the U.S.
| California | University of California, San Francisco, San Francisco |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.